Literature DB >> 18313449

Maternal C-reactive protein and developmental programming of atherosclerosis.

Antonio Liguori1, Francesco P D'Armiento, Antonio Palagiano, Wulf Palinski, Claudio Napoli.   

Abstract

OBJECTIVE: Maternal hypercholesterolemia during pregnancy enhances the susceptibility to atherosclerosis in their offspring by oxidation-dependent mechanisms. The present study investigated whether maternal C-reactive protein (CRP) level, which is an indicator of inflammation and cardiovascular risk, or smoking, which enhances oxidative stress, predict the in utero programming of atherosclerosis. STUDY
DESIGN: Subsets of patients from the Fate of Early Lesions in Childhood study (156 normocholesterolemic children) were examined at autopsy, classified by maternal cholesterol levels during pregnancy. Maternal CRP level was correlated with maternal cholesterol and aortic atherosclerosis of children.
RESULTS: CRP level was elevated in hypercholesterolemic mothers and showed significant correlation with atherogenesis in children in univariate and multivariate analysis. However, many hypercholesterolemic mothers did not have elevated CRP levels. Smoking only correlated in univariate analysis.
CONCLUSION: CRP level during pregnancy is a predictor of increased atherogenesis in children of hypercholesterolemic mothers, albeit a weaker one than maternal cholesterol. In the presence of hypercholesterolemia, maternal smoking does not further enhance atherogenic programming.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313449     DOI: 10.1016/j.ajog.2007.11.027

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

1.  Epigenetic Hallmarks of Fetal Early Atherosclerotic Lesions in Humans.

Authors:  Filomena de Nigris; Francesco Cacciatore; Francesco P Mancini; Dino F Vitale; Gelsomina Mansueto; Francesco P D'Armiento; Concetta Schiano; Andrea Soricelli; Claudio Napoli
Journal:  JAMA Cardiol       Date:  2018-12-01       Impact factor: 14.676

Review 2.  Developmental mechanisms involved in the primary prevention of atherosclerosis and cardiovascular disease.

Authors:  Claudio Napoli
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

Review 3.  Influence of maternal dysmetabolic conditions during pregnancy on cardiovascular disease.

Authors:  Wulf Palinski; Eric Nicolaides; Antonio Liguori; Claudio Napoli
Journal:  J Cardiovasc Transl Res       Date:  2009-05-29       Impact factor: 4.132

Review 4.  Developmental programming and hypertension.

Authors:  Anne Monique Nuyt; Barbara T Alexander
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-03       Impact factor: 2.894

5.  Changes in serum lipid levels during pregnancy in type 1 and type 2 diabetic subjects.

Authors:  Christian S Göbl; Ammon Handisurya; Katharina Klein; Latife Bozkurt; Anton Luger; Dagmar Bancher-Todesca; Alexandra Kautzky-Willer
Journal:  Diabetes Care       Date:  2010-06-02       Impact factor: 17.152

Review 6.  Fetoplacental vascular endothelial dysfunction as an early phenomenon in the programming of human adult diseases in subjects born from gestational diabetes mellitus or obesity in pregnancy.

Authors:  Andrea Leiva; Fabián Pardo; Marco A Ramírez; Marcelo Farías; Paola Casanello; Luis Sobrevia
Journal:  Exp Diabetes Res       Date:  2011-11-24

7.  Circulating TRAIL shows a significant post-partum decline associated to stressful conditions.

Authors:  Giorgio Zauli; Lorenzo Monasta; Erika Rimondi; Liza Vecchi Brumatti; Oriano Radillo; Luca Ronfani; Marcella Montico; Giuseppina D'Ottavio; Salvatore Alberico; Paola Secchiero
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

8.  Maternal low-protein diet or hypercholesterolemia reduces circulating essential amino acids and leads to intrauterine growth restriction.

Authors:  Kum Kum S Bhasin; Atila van Nas; Lisa J Martin; Richard C Davis; Sherin U Devaskar; Aldons J Lusis
Journal:  Diabetes       Date:  2008-12-10       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.